Literature DB >> 3801276

Growth rate of primary breast cancer and prognosis: observations on a 3- to 7-year follow-up in 180 breast cancers.

E Galante, G Gallus, A Guzzon, A Bono, G Bandieramonte, S Di Pietro.   

Abstract

The disease-free probabilities after 3 to 7 years of follow-up of 180 breast cancers of known doubling times were studied to assess the prognostic significance and clinical implications of the growth characteristics of primary breast cancer. Fast-growing tumours, N+ greater than 3, showed a prognosis significantly worse (P less than 0.01) than that of slow-growing tumours of the same class; no significant differences were found among N- or N+ (1-3) fast-, intermediate- and slow-growing tumours. Highly significant differences were found among fast- and intermediate-growing tumours with different degrees of lymph node involvement (respectively P less than 0.0001 and P less than 0.001), with the worst prognosis for N+ greater than 3 tumours. In contrast, no significant differences were found among slow-growing tumours of the different N classes. When the Cox model was applied, the relationship between lymph node involvement and doubling time was significant, as was the interaction term. It is suggested that growth rate and metastatic potential are not the same in primary breast cancers, and their relation should be investigated.

Entities:  

Mesh:

Year:  1986        PMID: 3801276      PMCID: PMC2001550          DOI: 10.1038/bjc.1986.247

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

1.  The cross rates of growth of human mammary carcinoma.

Authors:  S Kusama; J S Spratt; W L Donegan; F R Watson; C Cunningham
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

2.  Long term prognosis of women with breast cancer in New Zealand: study of survival to 30 years.

Authors:  A D Hibberd; L J Horwood; J E Wells
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-04

3.  Therapeutic implications from a mathematical model characterizing the course of breast cancer.

Authors:  N H Slack; L E Blumenson; I D Bross
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

4.  Acute carcinoma of the breast.

Authors:  J S Spratt; A F Chang; L S Heuser; J G Kuhns; J B Buchanan; H C Polk
Journal:  Surg Gynecol Obstet       Date:  1983-09

5.  Breast cancer--influence of growth rate on prognosis and treatment evaluation: a study based on mastectomy scar recurrences.

Authors:  A W Pearlman
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

6.  Prognostic significance of the growth rate of breast cancer: preliminary evaluation on the follow-up of 196 breast cancers.

Authors:  E Galante; A Guzzon; G Gallus; M Mauri; A Bono; A De Carli; M Merson; S Di Pietro
Journal:  Tumori       Date:  1981-08
  6 in total
  5 in total

Review 1.  Natural history of human breast cancer: recent data and clinical implications.

Authors:  M Tubiana; S Koscielny
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

2.  Breast mammography and tumour volume.

Authors:  J F Robertson; J Caseldine; S Winfield
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

3.  Machine learning-based prediction of breast cancer growth rate in vivo.

Authors:  Shristi Bhattarai; Sergey Klimov; Mohammed A Aleskandarany; Helen Burrell; Anthony Wormall; Andrew R Green; Padmashree Rida; Ian O Ellis; Remus M Osan; Emad A Rakha; Ritu Aneja
Journal:  Br J Cancer       Date:  2019-08-09       Impact factor: 7.640

4.  In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients.

Authors:  Tae-Kyung Yoo; Jun Won Min; Min Kyoon Kim; Eunshin Lee; Jongjin Kim; Han-Byoel Lee; Young Joon Kang; Yun-Gyoung Kim; Hyeong-Gon Moon; Woo Kyung Moon; Nariya Cho; Dong-Young Noh; Wonshik Han
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

5.  Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review.

Authors:  Meryl Dahan; Delphine Hequet; Claire Bonneau; Xavier Paoletti; Roman Rouzier
Journal:  Cancer Med       Date:  2021-07-15       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.